TDAC Q3 2023 Earnings Report — Translational Development Acquisition Corp. Revenue & Financial Results | Market Cap Arena

Translational Development Acquisition Corp.TDAC

Q3 2023 Earnings

Reported September 30, 2023

Quarter Comparison

Revenue

Operating Income

EPS (Diluted)

Free Cash Flow

Metric	Q3 2023	Q2 2023	Q3 2022	QoQ Change	YoY Change
Revenue	$0	$0	—	—	—
Op. Income	-$500	-$602	—	16.9%	—
EPS (Diluted)	$-0.00	$-0.00	—	0.0%	—
Free Cash Flow	$0	-$102	—	100.0%	—

Income Statement

Item	Amount
REVENUE	$0
Cost of Revenue	$0
GROSS PROFIT	$0
R&D Expenses	$0
Selling & Marketing	$0
General & Administrative	$500
SG&A Expenses	$500
Other Expenses	$0
Operating Expenses	$500
Cost & Expenses	$500
OPERATING INCOME	-$500
Interest Income	$0
Interest Expense	$0
Other Income/Expenses	$0
INCOME BEFORE TAX	-$500
Income Tax Expense	$0
Net Income from Continuing Ops	-$500
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	-$500
Net Income Deductions	$0
BOTTOM LINE NET INCOME	-$500
D&A	$0
EBIT	-$500
EBITDA	-$500
EPS	-$0
EPS Diluted	-$0

Cash Flow Statement

Item	Amount
Net Income	-$500
Depreciation & Amortization	$0
Stock-Based Compensation	$0
Deferred Income Tax	$0
Other Non-Cash Items	$0
Change in Working Capital	$500
OPERATING CASH FLOW	$0
Capital Expenditure	$0
Acquisitions (Net)	$0
Purchases of Investments	$0
Sales/Maturities of Investments	$0
Other Investing Activities	$0
NET CASH FROM INVESTING	$0
Net Debt Issuance	$0
Common Stock Repurchased	$0
Common Dividends Paid	$0
Other Financing Activities	$0
NET CASH FROM FINANCING	$0
FREE CASH FLOW	$0
Net Change in Cash	$0